DEVYSER DIAGNOSTICS AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 105 SEK | +1.94% |
|
+0.96% | +33.59% |
| Apr. 25 | Devyser Receives IVDR Approval for Post-Transplant Monitoring Software | CI |
| Mar. 11 | Devyser Diagnostics AB Achieves Breakthrough in the US with Cystic Fibrosis NGS Test | CI |
| Sales 2024 * | 250M 22.84M | Sales 2025 * | 342M 31.29M | Capitalization | 1.71B 156M |
|---|---|---|---|---|---|
| Net income 2024 * | -3M -274K | Net income 2025 * | 37M 3.38M | EV / Sales 2024 * | 5.99 x |
| Net cash position 2024 * | 214M 19.56M | Net cash position 2025 * | 228M 20.83M | EV / Sales 2025 * | 4.33 x |
| P/E ratio 2024 * |
-457
x | P/E ratio 2025 * |
43.5
x | Employees | 118 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 51.4% |
More Fundamentals
* Assessed data
More news
Latest transcript on Devyser Diagnostics AB
More press releases
| 1 day | +1.94% | ||
| 1 week | +0.96% | ||
| Current month | +3.45% | ||
| 1 month | +3.96% | ||
| 3 months | +17.98% | ||
| 6 months | +71.01% | ||
| Current year | +33.59% |
1 week
102.00
107.00
1 month
100.00108.50
Current year
76.20109.00
1 year
57.40109.00
3 years
56.10109.00
5 years
56.10109.00
10 years
56.10109.00
| Managers | Title | Age | Since |
|---|---|---|---|
Ulf Axel Klangby
FOU | Founder | 55 | 03-12-31 |
Fredrik Alpsten
CEO | Chief Executive Officer | 58 | - |
Sabina Berlin
DFI | Director of Finance/CFO | 41 | 20-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 70 | 20-12-31 | |
| Director/Board Member | 52 | 21-12-31 | |
| Chairman | 55 | 09-12-31 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 105 | +1.94% | 2,387 |
| 24-04-25 | 103 | +0.49% | 4,243 |
| 24-04-24 | 102.5 | -1.44% | 455 |
| 24-04-23 | 104 | +1.46% | 12,234 |
| 24-04-22 | 102.5 | -1.44% | 4,039 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am EDT
More quotes
Devyser Diagnostics AB is a Sweden-based company engaged in development, manufacture ad sale of kits for genetic testing in routing diagnostic to laboratories. The products are used for complex deoxyribonucleic acid (DNA) testing in the areas of hereditary diseases, oncology, and post-transplantation monitoring in order to diagnose genetic diseases and target cancer treatment. The company has since its inception developed and launched almost 30 products for routine diagnostic use, including Devyser Thrombophilia assay as well as Devyser Resolution XY for analysis of chromosomes X and Y. Devyser Diagnosticsâ products are sold directly to the end customer or through hired distributors. The Company provides its products in more than 45 countries.
Calendar
2024-05-07
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
66.88
DKK
Average target price
82.33
DKK
Spread / Average Target
+23.10%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +33.59% | 156M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- DVYSR Stock
